Objective The gene TNFRSF11B encodes for osteoprotegerin (OPG) and was recently identified as the CCAL1 locus associated with familial calcium pyrophosphate deposition disease (CPDD). While the CCAL1 OPG mutation (OPG‐XL) was originally believed to be a gain‐of‐function mutation, loss of OPG activity causes arthritis‐associated osteolysis in mice, which is likely related to excess subchondral osteoclast formation and/or activity. The purpose of the present study was to further explore the effect of OPG‐XL in osteoclastogenesis. Methods The effects of recombinant OPG‐XL and wild‐type (WT) OPG were determined in monoculture and coculture models of RANKL‐induced osteoclastogenesis. The effects of OPG‐XL on osteoclast survival as well as on TRAIL‐induced apoptosis were determined using standard in vitro assays and compared to WT OPG. The ability of OPG‐XL and WT OPG to bind to osteoblasts was measured with enzyme‐linked immunosorbent assay and flow cytometry using the osteoblastic MC3T3‐E1 cell line. Results OPG‐XL was less effective than WT OPG at blocking RANKL‐induced osteoclastogenesis in monoculture and coculture models. Osteoclast survival and inhibition of TRAIL‐induced apoptosis were similar in the presence of OPG‐XL and WT OPG. Compared to WT OPG, considerably less OPG‐XL bound to cells. Conclusion These findings indicate that OPG‐XL is a loss‐of‐function mutation as it relates to RANKL‐mediated osteoclastogenesis, and thus may permit increased osteoclast numbers and heightened bone turnover. Further studies are necessary to demonstrate how this mutation contributes to arthritis in individuals carrying this mutation.